Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase II Study of Docetaxel, Cisplatin, and Irinotecan (TPC) in Advanced Esophageal and Gastric Cancer

Phase II Study of Docetaxel, Cisplatin, and Irinotecan (TPC) in Advanced Esophageal and Gastric Cancer. Ca Invest. 2005; 23(S1):30.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.